Cargando…

Identification of the APC/C co-factor FZR1 as a novel therapeutic target for multiple myeloma

Multiple Myeloma (MM) is a haematological neoplasm characterised by the clonal proliferation of malignant plasma cells in the bone marrow. The success of proteasome inhibitors in the treatment of MM has highlighted the importance of the ubiquitin proteasome system (UPS) in the pathogenesis of this d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crawford, Lisa J., Anderson, Gordon, Johnston, Cliona K., Irvine, Alexandra E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342567/ https://www.ncbi.nlm.nih.gov/pubmed/27655696 http://dx.doi.org/10.18632/oncotarget.12026

Ejemplares similares

Targeting of Fzr/Cdh1 for timely activation of the APC/C at the centrosome during mitotic exit
por: Meghini, Francesco, et al.
Publicado: (2016)

Revisiting degron motifs in human AURKA required for its targeting by APC/C(FZR1)
por: Abdelbaki, Ahmed, et al.
Publicado: (2022)

APC/C(FZR-1) Controls SAS-5 Levels To Regulate Centrosome Duplication in Caenorhabditis elegans
por: Medley, Jeffrey C., et al.
Publicado: (2017)

APC(FZR1) prevents nondisjunction in mouse oocytes by controlling meiotic spindle assembly timing
por: Holt, Janet E., et al.
Publicado: (2012)

Workshop on a Project for a FZR-beamline at ESRF
por: Matz, Wolfgang
Publicado: (1993)

A novel transcriptional cascade is involved in Fzr-mediated endoreplication
por: Qian, Wenliang, et al.
Publicado: (2020)

TRIM proteins in blood cancers
por: Crawford, Lisa J., et al.
Publicado: (2017)

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
por: Thomas, Alexandra L., et al.
Publicado: (2015)

FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
por: Liu, Shuo, et al.
Publicado: (2020)

Fzr/Cdh1 Promotes the Differentiation of Neural Stem Cell Lineages in Drosophila
por: Ly, Phuong Thao, et al.
Publicado: (2020)

Fzr regulates silk gland growth by promoting endoreplication and protein synthesis in the silkworm
por: Qian, Wenliang, et al.
Publicado: (2023)

The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma
por: Crawford, Lisa J., et al.
Publicado: (2020)

The roles of Fzy/Cdc20 and Fzr/Cdh1 in regulating the destruction of cyclin B in space and time
por: Raff, Jordan W., et al.
Publicado: (2002)

What are the roles of global DNA and APC 2 gene promotor hypermethylation in multiple myeloma?
por: Pehlivan, Sacide, et al.
Publicado: (2021)

Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
por: The, Inge, et al.
Publicado: (2015)

Multiple Myeloma
por: Crawford, A. Muir
Publicado: (1933)

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma
por: Ray, Arghya, et al.
Publicado: (2022)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Targeting the UPS as therapy in multiple myeloma
por: Chauhan, Dharminder, et al.
Publicado: (2008)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020)

Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
por: Brancati, Valentina Urzì, et al.
Publicado: (2023)

Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015
por: Bok, Robert A
Publicado: (2008)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

Phosphorylation of the Anaphase Promoting Complex activator FZR1/CDH1 is required for Meiosis II entry in mouse male germ cell
por: Tanno, Nobuhiro, et al.
Publicado: (2020)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

DPP8 is a novel therapeutic target for multiple myeloma
por: Sato, Tsutomu, et al.
Publicado: (2019)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Multiple myeloma metabolism – a treasure trove of therapeutic targets?
por: Roman-Trufero, Monica, et al.
Publicado: (2022)

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2011)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Transforming activity and therapeutic targeting of C-terminal Binding Protein 2 in Apc mutated neoplasia
por: Sumner, Evan T., et al.
Publicado: (2017)

Insights into APC/C: from cellular function to diseases and therapeutics
por: Zhou, Zhuan, et al.
Publicado: (2016)

CCS52A2/FZR1, a cell cycle regulator, is an essential factor for shoot apical meristem maintenance in Arabidopsis thaliana
por: Liu, Yajie, et al.
Publicado: (2012)

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Atomic-Resolution Structures of the APC/C Subunits Apc4 and the Apc5 N-Terminal Domain
por: Cronin, Nora B., et al.
Publicado: (2015)

PDK1 inhibition is a novel therapeutic target in multiple myeloma
por: Fujiwara, S, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u3cqnvqq7knvv0kl3ckcfpt0sb